Literature DB >> 1394807

In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model.

S Cros1, N Guilbaud, M Berlion, T Dunn, G Regnier, A Dhainaut, G Atassi, J P Bizzari.   

Abstract

S 9788, a new triazinoaminopiperidine derivative, was found to be a potent reversant of vincristine resistance in the in vivo murine leukemic P388/VCR model. In two treatment regimens (Q4D days 1, 5 and 9 and QD days 1-9), S 9788 enhanced the antitumor activity of vincristine in a dose-dependent manner, resulting in a complete circumvention of drug resistance for well-tolerated doses of S 9788. S 9788 was also effective in enhancing therapeutic effects of vincristine in the treatment of sensitive P388-bearing mice. These results strongly suggest that S 9788 may be a potential candidate for circumvention of multidrug resistance (MDR) in clinical practice.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1394807     DOI： 10.1007/bf00685604

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  15 in total

Review 1.  Pharmacology of drugs that alter multidrug resistance in cancer.

Authors:  J M Ford; W N Hait
Journal:  Pharmacol Rev       Date:  1990-09       Impact factor: 25.468

2.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

Authors:  F Thiebaut; T Tsuruo; H Hamada; M M Gottesman; I Pastan; M C Willingham
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 3.  Multiple-drug resistance in human cancer.

Authors:  I Pastan; M Gottesman
Journal:  N Engl J Med       Date:  1987-05-28       Impact factor: 91.245

Review 4.  Mechanism of multidrug resistance.

Authors:  G Bradley; P F Juranka; V Ling
Journal:  Biochim Biophys Acta       Date:  1988-08-03

5.  Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073.

Authors:  W Sato; N Fukazawa; T Suzuki; K Yusa; T Tsuruo
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

6.  Isolation and expression of a complementary DNA that confers multidrug resistance.

Authors:  P Gros; Y B Ben Neriah; J M Croop; D E Housman
Journal:  Nature       Date:  1986 Oct 23-29       Impact factor: 49.962

7.  Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.

Authors:  H L Pearce; A R Safa; N J Bach; M A Winter; M C Cirtain; W T Beck
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

8.  Cure of mice bearing P388 leukemia by vincristine in combination with a calcium channel blocker.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Treat Rep       Date:  1985-05

9.  Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.

Authors:  J M Zamora; H L Pearce; W T Beck
Journal:  Mol Pharmacol       Date:  1988-04       Impact factor: 4.436

10.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701
View more
  7 in total

1.  Inhibition of P-glycoprotein: rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an in vitro model of the blood-brain barrier.

Authors:  L Fenart; V Buée-Scherrer; L Descamps; C Duhem; M G Poullain; R Cecchelli; M P Dehouck
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

2.  Binding of a new multidrug resistance modulator, S9788, to human plasma proteins and erythrocytes.

Authors:  S Urien; P Nguyen; G Bastian; C Lucas; J P Tillement
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

3.  In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients.

Authors:  J Soudon; M Berlion; C Lucas; P Haddad; J P Bizzari; F Calvo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

Authors:  C J Punt; E E Voest; E Tueni; A T Van Oosterom; A Backx; P H De Mulder; B Hecquet; C Lucas; B Gerard; H Bleiberg
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.

Authors:  A M Julia; H Roché; M Berlion; C Lucas; G Milano; J Robert; J P Bizzari; P Canal
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

6.  In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance.

Authors:  P Mistry; J Plumb; S Eccles; S Watson; I Dale; H Ryder; G Box; P Charlton; D Templeton; P B Bevan
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models.

Authors:  T Watanabe; M Naito; T Oh-hara; Y Itoh; D Cohen; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1996-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.